Five Prime Thera (FPRX)

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

INVESTIGATION ALERT: Halper Sadeh LLP Investigates STAY, CUB, AEGN, FPRX; Shareholders are Encouraged to Contact the Firm

Lifshitz Law Firm, P.C. Announces Investigation of ATH, WIFI, BMTC, WSFS, DSSI, INSW, FPRX, FI, HWCC, and RMBL

SHAREHOLDER ALERT: WeissLaw LLP Reminds HWCC, FI, SVBI, and FRPX Shareholders About Its Ongoing Investigations

Halper Sadeh LLP Investigates the Following Mergers - TPCO, STAY, KSU, CUB, AEGN, FPRX; Shareholders Are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Reminds FI, SVBI, FRPX, and VKIN Shareholders About Its Ongoing Investigations

Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?

The drugmaker needs as much potential revenue as it can acquire at a reasonable price.

BREAKING NEWS ALERT: Halper Sadeh LLP Investigates CTB, FFG, PAND, SVBI, FPRX; Shareholders are Encouraged to Contact the Firm

Benefitfocus and Five Prime Therapeutics See Analyst Action

Indaba Capital wants a board “refresh” at benefits-management software firm Benefitfocus. Magnetar Capital disclosed a large stake in biopharmaceutical firm Prime Therapeutics.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of FRTA, AEGN, FPRX, and MIK Buyouts

SHAREHOLDER ALERT: WeissLaw LLP Reminds FI, SVBI, FRPX, and PAND Shareholders About Its Ongoing Investigations

INVESTIGATION ALERT: Halper Sadeh LLP Investigates WIFI, FFG, FPRX, PTVCA; Shareholders Are Encouraged to Contact the Firm

INVESTIGATION ALERT: Halper Sadeh LLP Investigates MGLN, FPRX, FLIR, WDR, HMSY, SNCA; Shareholders are Encouraged to Contact the Firm

FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

INVESTIGATION ALERT: Halper Sadeh LLP Investigates SVBI, FPRX, MIK, JCS; Shareholders Are Encouraged to Contact the Firm

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Five Prime Therapeutics, Inc. - FPRX

Moore Kuehn Encourages FPRX, SVBI, SOAC, and CAP Investors to Contact Law Firm

Amgen Acquires a Cancer Drug. Expect More Deals.

The biotech firm is building its pipeline by adding an experimental drug that could compete against Bristol Myers Squibb in treating deadly stomach cancers.

ALERT: Halper Sadeh LLP Investigates SVBI, FPRX, MIK, JCS; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc.

Notable Thursday Option Activity: FPRX, ZM, VECO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Five Prime Therapeutics, Inc (FPRX), where a total volume of 34,643 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 413.9% of FPRX's average daily trading volume over the past month, of 836,980 shares..

Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Five Prime Therapeutics, Inc. Buyout

Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.

FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm